Passage Bio Inc at Chardan Genetic Medicines Conference Transcript
(audio in progress) noon. It is now my pleasure to introduce our next guest, Dr. William Chou, President and CEO of Passage Bio. And the format for this is a fireside chat. So thank you for joining us today.
Questions & Answers
To start with, can you give us a high-level overview of Passage Bio and highlight any upcoming catalysts?
Be happy to. Thank you for having us. So we are an AAV gene therapy company focused on CNS disease. We do have a major catalyst coming up at the end of the year. This will be the first time we have shared clinical data from one of our gene therapy programs in frontotemporal dementia in patients with a granulin mutation.
We have two clinical-stage programs. One is in GM1 gangliosidosis, and the other one is in FTD. So we're pretty excited by what we're seeing out of the FTD trial. And we're excited to share
Access to All Earning Calls and Stock Analysis | |
30-Year Financial on one screen | |
All-in-one Stock Screener with unlimited filters | |
Customizable Stock Dashboard | |
Real Time Insider Trading Transactions | |
8,000+ Institutional investors’ 13F holdings | |
Powerful Excel Add-in and Google sheets Add-on | |
All data downloadable | |
Quick customer support | |
And much more... |